|1.||Pilon, Marinus: 2 articles (09/2011 - 11/2005)|
|2.||Pilon-Smits, Elizabeth A H: 2 articles (09/2011 - 11/2005)|
|3.||Pallauf, Josef: 2 articles (08/2006 - 11/2003)|
|4.||Mueller, Andreas S: 2 articles (08/2006 - 11/2003)|
|5.||Hill, Kristina E: 1 article (11/2015)|
|6.||Norsworthy, Brooke K: 1 article (11/2015)|
|7.||Byrne, Daniel W: 1 article (11/2015)|
|8.||Burk, Raymond F: 1 article (11/2015)|
|9.||Motley, Amy K: 1 article (11/2015)|
|10.||Sik Kim, Hyung: 1 article (10/2015)|
10/05/2015 - "Our findings may contribute to the development of selenate-based therapies for patients resistant to cancer drugs. "
09/01/2012 - "Nutritional and supranutritional levels of selenate differentially suppress prostate tumor growth in adult but not young nude mice."
06/08/2001 - "However, selenate showed no remarkable effect on all the steps of cancer cell invasion."
09/01/2012 - "Taken together, dietary selenate at nutritional and supranutritional levels differentially inhibit tumor development in adult, but not young, nude mice engrafted with PC-3 prostate cancer cells."
10/05/2015 - "Selenate specifically sensitizes drug-resistant cancer cells by increasing apoptosis via G2 phase cell cycle arrest without P-GP inhibition."
|2.||Colonic Neoplasms (Colon Cancer)
01/01/1999 - "This study examined whether selenite, selenate or selenomethionine would be protective against 3, 2'-dimethyl-4-aminobiphenyl (DMABP)-DNA adduct formation in the liver and colon of rats and sought to delineate the mechanism for the protective effects of the different chemical forms of selenium against aberrant crypt formation, a preneoplastic lesion for colon cancer. "
07/01/1995 - "Only a transient insulinotropic effect with improved glucose tolerance is induced during acute selenate exposure, and is followed by progressive development of hyperglycemia indicating selenate toxicity."
01/01/2014 - "Long-term supranutritional supplementation with selenate decreases hyperglycemia and promotes fatty liver degeneration by inducing hyperinsulinemia in diabetic db/db mice."
07/01/1995 - "That effect of selenate was lost with progression of the experiment during the second hour of the IVGTT, when plasma glucose continued to decline slowly in control experiments, but increased in selenate exposed rats without any adequate insulin secretory response to hyperglycemia. "
01/01/2014 - "Taken together, these results suggest that dietary selenate supplementation in db/db mice decreased hyperglycemia by increasing insulin production and secretion; however, long-term hyperinsulinemia eventually led to reduced antioxidant defense capacity, which exacerbated fatty liver degeneration. "
|4.||Body Weight (Weight, Body)
08/25/2001 - "In time-course experiments, 82Se-enriched selenate and selenite were injected at doses of 50 and 10 microg/kg body weight, respectively, and the animals were sacrificed 5, 15, 30, 60 and 180 min later. "
08/25/2001 - "In dose-relation experiments, 82Se-enriched selenate or selenite was injected intravenously into male Wistar rats of 8 weeks of age (three rats/group) at single doses of 10, 25, 50, 100 and 200 microg/kg body weight for the selenate group, and 2, 5, 10, 25 and 50 microg/kg body weight for the selenite group. "
12/01/1996 - "A high-selenium group (n = 7, mean body weight = 1312 g) received selenate-fortified preterm and full-term infant formulas containing 0.36 and 0.22 mumol Se/L, respectively, and a low-selenium group (n = 10, mean body weight = 1262 g) received non-selenium-fortified preterm and full-term infant formulas containing 0.12 and 0.11 mumol Se/L, respectively. "
01/01/1996 - "Since selenate induced a moderate decrease in body weight due to an anorexigenic effect, we checked that there was no improvement of glucose homeostasis or hepatic glucose metabolism in an additional group of calorie-restricted diabetic rats, which was weight-matched with the selenate group. "
08/01/1999 - "The metabolic pathway for and metabolites of selenium (Se) administered intravenously to rats in the form of selenate at a dose of 0.3 mg Se kg-1 body weight were studied by speciating Se in the bloodstream, liver and urine by HPLC-inductively coupled argon plasma mass spectrometry. "
08/01/2006 - "In type II diabetic animals, a reduction of insulin resistance could be shown as an outcome of selenate treatment. "
11/01/2003 - "However the current study revealed an insulinomimetic role for selenate (selenium VI) also in type II diabetic animals due to a melioration of insulin resistance. "
08/01/2006 - "The expression of peroxisome proliferator-activated receptor gamma (PPARgamma), another important factor in the context of insulin resistance and lipid metabolism, was significantly increased by selenate application. "
08/01/2006 - "Selenate treatment reduced insulin resistance significantly and reduced the activity of liver cytosolic protein tyrosine phosphatases (PTPs) as negative regulators of insulin signalling by about 50%. "
11/01/2003 - "After 10 weeks a distinct melioration of the diabetic status indicated by a corrected glucose tolerance and a lowered insulin resistance was measured in selenate treated mice (group SeVI) in comparison to their selenium deficient and selenite treated companions and to their initial status. "
|2.||Sodium Selenite (Selenite)
|6.||DNA (Deoxyribonucleic Acid)
|8.||Protein Isoforms (Isoforms)
|1.||Heterologous Transplantation (Xenotransplantation)